Valuation: Beta Bionics, Inc.

Market Cap 715M 619M 578M 530M 997M 68.08B 1.01B 6.78B 2.66B 34.12B 2.69B 2.63B 113B P/E 2026 *
-7.43x
P/E 2027 * -7.38x
Enterprise Value 578M 500M 467M 428M 806M 55.01B 818M 5.48B 2.15B 27.57B 2.17B 2.12B 91.15B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 3.53x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day+12.69%
1 week+23.93%
Current month+23.93%
1 month-1.73%
3 months+64.77%
6 months+21.56%
Current year-47.82%
1 week 12.73
Extreme 12.73
16.58
1 month 12.73
Extreme 12.73
18.2
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 14/08/2022
Director of Finance/CFO 37 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 31/01/2020
Director/Board Member 50 14/08/2022
Director/Board Member 63 30/09/2024
Date Insider Type Main position Quantity % Market Cap.
24/06/26 Sell

Executive/Senior Manager

-1,258 0.0028%
27/02/26 Free

Chief Technology Officer

110,131 0.2502%
27/02/26 Sell

Executive/Senior Manager

59,813 0.1359%
Change 5-day change 1-year change 3-year change Capi.($)
+12.69%+23.93%+7.87% - 715M
+2.41%+3.43%+28.93%+6.88% 220B
+2.39%+5.02%+2.09%-20.96% 144B
+1.36%+7.21%-19.42%+25.07% 134B
+0.02%+5.52%-52.19%-2.51% 71.46B
+0.45%+4.24%+14.51%+14.16% 51.71B
+1.05%+7.19%-14.90%-17.93% 50.84B
+3.28%+5.49%+27.35%+13.73% 41.23B
+1.79%+7.83%+44.69%+37.11% 39.95B
+2.08%+5.51%-0.32%-2.92% 32.42B
Average +2.75%+7.39%+3.86%+5.85% 78.57B
Weighted average by Cap. +1.80%+5.19%+4.11%+4.39%

Financials

2026 *2027 *
Net sales 134M 116M 108M 99.16M 187M 12.74B 189M 1.27B 498M 6.38B 502M 491M 21.1B 180M 155M 145M 133M 251M 17.11B 255M 1.7B 669M 8.58B 675M 660M 28.35B
Net income -95.09M -82.25M -76.81M -70.46M -133M -9.05B -135M -901M -354M -4.54B -357M -349M -15B -96.42M -83.4M -77.88M -71.45M -134M -9.18B -137M -914M -359M -4.6B -362M -354M -15.2B
Net Debt -137M -119M -111M -102M -191M -13.07B -194M -1.3B -511M -6.55B -516M -504M -21.66B -81.06M -70.12M -65.48M -60.07M -113M -7.71B -115M -768M -302M -3.87B -304M -298M -12.78B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
07/08/26 US$15.90 +12.69% 1,274,256
06/08/26 US$14.11 +1.44% 590,198
05/08/26 US$13.91 -4.53% 897,075
04/08/26 US$14.57 +9.14% 3,341,441
03/08/26 US$13.35 +4.05% 2,820,101
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.90USD
Average target price
20.08USD
Spread / Average Target
+26.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock